Press Release Details

Stay on top of the latest news from Poseida Therapeutics. Learn about our leading-edge cell and gene therapy programs, from new discoveries to clinical trials, and get the most recent investor news.

Poseida Therapeutics Announces Notice of Allowance for New Patents and Registration of New Trademarks

02/13/2019 at 8:00 AM EST

Key Patent Covers Manufacture of Therapeutic Products Containing a High Percentage of T Stem Cell Memory Cells

SAN DIEGO, Feb. 13, 2019 (GLOBE NEWSWIRE) -- Poseida Therapeutics Inc., a clinical-stage biopharmaceutical company leveraging proprietary non-viral gene engineering technologies to create life-saving therapeutics, today announced that the U.S. Patent and Trademark Office (USPTO) has issued a Notice of Allowance for a patent protecting the method of producing genetically modified T cells with a high percentage of stem cell memory T cells (Tscm).

Tscm cells are long-lived, self-renewing and multipotent. These cells have the capacity to reconstitute the entire spectrum of effector and memory T cells subsets and usually survive for decades and potentially for entire lifespans. The wholly-owned patent covers the method of producing genetically modified T cell products that are comprised of 25% or more Tscm cells.

“These additions to our patent portfolio further validate the novel advancements we have made in Tscm-based product candidates,” said Eric Ostertag, M.D., Ph.D., chief executive officer of Poseida. “Our innovative CAR-T product candidates, utilizing a proprietary non-viral delivery method, are comprised of a high percentage of stem cell memory T cells, which we believe are important for safety and efficacy of CAR-T approaches to treat both liquid and solid tumors.”

The Company’s lead product candidate, P-BCMA-101, is an autologous CAR-T therapeutic candidate to treat patients with relapsed/refractory multiple myeloma. This and other product candidates currently in development are comprised of a high percentage of Tscm cells.

The Company has also received a Notice of Allowance on a patent that is part of a broader portfolio protecting its piggyBac® DNA Modification System, a proprietary non-viral DNA delivery method. The Company also received approval for registered trademarks of both “piggyBac” and “Footprint-Free®”, the latter referring to a platform technology designed to allow for gene editing of as little as a single nucleotide in 100% of target cells.

About Poseida Therapeutics, Inc.
Poseida Therapeutics is a clinical-stage biotechnology company leveraging proprietary next-generation non-viral, gene engineering technologies to create life-saving therapeutics for patients with high unmet medical need. The company is developing a wholly-owned pipeline of autologous and allogeneic CAR-T product candidates, initially focused on the treatment of hematological malignancies and solid tumors. Poseida’s product candidates are designed to address the limitations of other CAR-T therapies, including duration of response, the ability to treat solid tumors and safety concerns.

Contacts:
Marcy Graham
VP, Corporate Affairs
Poseida Therapeutics, Inc.
858-779-3108 
mgraham@poseida.com

Jason Spark
Canale Communications 
619-849-6005
jason@canalecomm.com